Recent clinical trials have shown that the efficacy of adalimumab biosimilars is similar to that of brand-name adalimumab. However, real-world data on the efficacy of adalimumab biosimilars don’t exist. This study aims to examine the outcomes after a mandatory nonmedical switch from adalimumab originator to adalimumab biosimilars in patients with psoriasis.
This cohort study included a total of 348 patients with psoriasis who were treated with an adalimumab originator. Eligible patients underwent a mandatory nonmedical switch from adalimumab originator to adalimumab biosimilars. The primary outcome of the study was one-year drug retention in patients switching to adalimumab biosimilars compared with those who continued with the adalimumab originator.
The one-year drug retention rates were 92.0% for the adalimumab biosimilar cohort and 92.1% for the adalimumab originator cohort. Hazard ratios were also the same between the two cohorts. The crude hazard ratios were 1.02 for all causes of drug discontinuation, 0.82 for insufficient effect, and 1.41 for adverse events for the adalimumab biosimilar cohort when compared with the originator cohort.
The findings suggested that one-year drug retention rates were similar among the two cohorts, and a switch from adalimumab originator to adalimumab biosimilars wasn’t associated with drug retention.
Ref: https://jamanetwork.com/journals/jamadermatology/article-abstract/2778168?resultClick=1
